Seelos therapeutics doses first patient in an open label basket study of sls-005 in amyotrophic lateral sclerosis in australia and provides an enrollment update of its study on the healey als platform

Sls-005 study on the healey als platform is expected to complete enrollment this quarter; top-line data readout expected mid-2023 new york , july 18, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in an open-label basket study of sls-005 (trehalose injection, 90.5 mg/ml for intravenous infusion) for the treatment of patients with amyotrophic lateral sclerosis (als or lou gehrig's disease) in australia.    seelos plans to conduct this 24-week, open-label basket study (actrn: 12621001755820) in australia to evaluate the effectiveness of sls-005 on disease progression and severity, as well as its safety and tolerability, in participants with als, spinocerebellar ataxia and huntington's disease.
SEEL Ratings Summary
SEEL Quant Ranking